|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vargo-Gogola T and Rosen JM: Modelling
breast cancer: One size does not fit all. Nat Rev Cancer.
7:659–672. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mandlekar S and Kong AN: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qadir MA, Kwok B, Dragowska WH, To KH, Le
D, Bally MB and Gorski SM: Macroautophagy inhibition sensitizes
tamoxifen-resistant breast cancer cells and enhances mitochondrial
depolarization. Breast Cancer Res Treat. 112:389–403. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun X, Jiao X, Pestell TG, Fan C, Qin S,
Mirabelli E, Ren H and Pestell RG: MicroRNAs and cancer stem cells:
The sword and the shield. Oncogene. 33:4967–4977. 2014. View Article : Google Scholar
|
|
7
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar :
|
|
8
|
Fatica A and Fazi F: MicroRNA-regulated
pathways in hemato-logical malignancies: How to avoid cells playing
out of tune. Int J Mol Sci. 14:20930–20953. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang
JR, Zeng C and Zhuang SM: MicroRNA-26a/b and their host genes
cooperate to inhibit the G1/S transition by activating the pRb
protein. Nucleic Acids Res. 40:4615–4625. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang B, Liu XX, He JR, Zhou CX, Guo M, He
M, Li MF, Chen GQ and Zhao Q: Pathologically decreased miR-26a
antagonizes apoptosis and facilitates carcinogenesis by targeting
MTDH and EZH2 in breast cancer. Carcinogenesis. 32:2–9. 2011.
View Article : Google Scholar
|
|
11
|
Liu P, Tang H, Chen B, He Z, Deng M, Wu M,
Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour
proliferation and metastasis by targeting metadherin in triple
negative breast cancer. Cancer Lett. 357:384–392. 2015. View Article : Google Scholar
|
|
12
|
Jansen MPHM, Reijm EA, Sieuwerts AM,
Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA,
Martens JW, Sleijfer S, Foekens JA, et al: High miR-26a and low
CDC2 levels associate with decreased EZH2 expression and with
favorable outcome on tamoxifen in metastatic breast cancer. Breast
Cancer Res Treat. 133:937–947. 2012. View Article : Google Scholar :
|
|
13
|
Joshi T, Elias D, Stenvang J, Alves CL,
Teng F, Lyng MB, Lykkesfeldt AE, Brünner N, Wang J, Gupta R, et al:
Integrative analysis of miRNA and gene expression reveals
regulatory networks in tamoxifen-resistant breast cancer.
Oncotarget. 7:57239–57253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeGregori J and Johnson DG: Distinct and
overlapping roles for E2F family members in transcription,
proliferation and apoptosis. Curr Mol Med. 6:739–748.
2006.PubMed/NCBI
|
|
15
|
Logan N, Delavaine L, Graham A, Reilly C,
Wilson J, Brummelkamp TR, Hijmans EM, Bernards R and La Thangue NB:
E2F-7: A distinctive E2F family member with an unusual organization
of DNA-binding domains. Oncogene. 23:5138–5150. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Endo-Munoz L, Dahler A, Teakle N, Rickwood
D, Hazar-Rethinam M, Abdul-Jabbar I, Sommerville S, Dickinson I,
Kaur P, Paquet-Fifield S, et al: E2F7 can regulate proliferation,
differentiation, and apoptotic responses in human keratinocytes:
Implications for cutaneous squamous cell carcinoma formation.
Cancer Res. 69:1800–1808. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Stefano L, Jensen MR and Helin K: E2F7,
a novel E2F featuring DP-independent repression of a subset of
E2F-regulated genes. EMBO J. 22:6289–6298. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zalmas LP, Zhao X, Graham AL, Fisher R,
Reilly C, Coutts AS and La Thangue NB: DNA-damage response control
of E2F7 and E2F8. EMBO Rep. 9:252–259. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Q, Qiu XM, Li QH, Wang XY, Li L, Xu M,
Dong M and Xiao YB: MicroRNA-424 may function as a tumor suppressor
in endometrial carcinoma cells by targeting E2F7. Oncol Rep.
33:2354–2360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reimer D, Sadr S, Wiedemair A, Stadlmann
S, Concin N, Hofstetter G, Müller-Holzner E, Marth C and Zeimet AG:
Clinical relevance of E2F family members in ovarian cancer - an
evaluation in a training set of 77 patients. Clin Cancer Res.
13:144–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hazar-Rethinam M, de Long LM, Gannon OM,
Topkas E, Boros S, Vargas AC, Dzienis M, Mukhopadhyay P, Simpson F,
Endo-Munoz L, et al: A novel E2F/sphingosine kinase 1 axis
regulates anthracycline response in squamous cell carcinoma. Clin
Cancer Res. 21:417–427. 2015. View Article : Google Scholar
|
|
22
|
Thrane S, Lykkesfeldt AE, Larsen MS,
Sorensen BS and Yde CW: Estrogen receptor α is the major driving
factor for growth in tamoxifen-resistant breast cancer and
supported by HER/ERK signaling. Breast Cancer Res Treat. 139:71–80.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cui J, Yang Y, Li H, Leng Y, Qian K, Huang
Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERα
transcriptional activity and tamoxifen resistance via targeting
CDK3 in breast cancer cells. Oncogene. 34:3895–3907. 2015.
View Article : Google Scholar
|
|
24
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thürlimann B and Senn HJ; Panel members: Thresholds for
therapies: Highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pang Y, Liu J, Li X, Zhang Y, Zhang B,
Zhang J, Du N, Xu C, Liang R, Ren H, et al: Nano Let 7b
sensitization of eliminating esophageal cancer stem like cells is
dependent on blockade of Wnt activation of symmetric division. Int
J Oncol. 51:1077–1088. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-DeltaDeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Lim YY, Wright JA, Attema JL, Gregory PA,
Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y, et
al: Epigenetic modulation of the miR-200 family is associated with
transition to a breast cancer stem-cell-like state. J Cell Sci.
126:2256–2266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Licchesi JD, Van Neste L, Tiwari VK, Cope
L, Lin X, Baylin SB and Herman JG: Transcriptional regulation of
Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene. 29:5923–5934.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Salvatori B, Iosue I, Mangiavacchi A,
Loddo G, Padula F, Chiaretti S, Peragine N, Bozzoni I, Fazi F and
Fatica A: The microRNA-26a target E2F7 sustains cell proliferation
and inhibits monocytic differentiation of acute myeloid leukemia
cells. Cell Death Dis. 3:e4132012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tao J, Zhao X and Tao J: c-MYC-miRNA
circuitry: A central regulator of aggressive B-cell malignancies.
Cell Cycle. 13:191–198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao X, Lwin T, Zhang X, Huang A, Wang J,
Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E and Tao J:
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell
lymphoma survival and clonogenicity. Leukemia. 27:2341–2350. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ward A, Balwierz A, Zhang JD, Küblbeck M,
Pawitan Y, Hielscher T, Wiemann S and Sahin Ö: Re-expression of
microRNA-375 reverses both tamoxifen resistance and accompanying
EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013.
View Article : Google Scholar
|
|
33
|
Zhu J, Zou Z, Nie P, Kou X, Wu B, Wang S,
Song Z and He J: Downregulation of microRNA-27b-3p enhances
tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1
expression. Cell Death Dis. 7:e24542016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S,
Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222
confers tamoxifen resistance in breast cancer by targeting p27Kip1.
J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu
YX, Liu JF and He ZM: miR-26a suppresses tumor growth and
metastasis by targeting FGF9 in gastric cancer. PLoS One.
8:e726622013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang X, Liang L, Zhang XF, Jia HL, Qin Y,
Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al: MicroRNA-26a
suppresses tumor growth and metastasis of human hepatocellular
carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology.
58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding
J, Liang L, Hu J, Shen H, Chen Z, et al: MicroRNA-26a acts as a
tumor suppressor inhibiting gallbladder cancer cell proliferation
by directly targeting HMGA2. Int J Oncol. 44:2050–2058. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin G, Liu B, Meng Z, Liu Y, Li X, Wu X,
Zhou Q and Xu K: MiR-26a enhances invasive capacity by suppressing
GSK3β in human lung cancer cells. Exp Cell Res. 352:364–374. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qian X, Zhao P, Li W, Shi ZM, Wang L, Xu
Q, Wang M, Liu N, Liu LZ and Jiang BH: MicroRNA-26a promotes tumor
growth and angiogenesis in glioma by directly targeting prohibitin.
CNS Neurosci Ther. 19:804–812. 2013.PubMed/NCBI
|
|
40
|
Shen W, Song M, Liu J, Qiu G, Li T, Hu Y
and Liu H: MiR-26a promotes ovarian cancer proliferation and
tumorigenesis. PLoS One. 9:e868712014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chu J, Zhu Y, Liu Y, Sun L, Lv X, Wu Y, Hu
P, Su F, Gong C, Song E, et al: E2F7 overexpression leads to
tamoxifen resistance in breast cancer cells by competing with E2F1
at miR-15a/16 promoter. Oncotarget. 6:31944–31957. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang X, Zhao X, Fiskus W, Lin J, Lwin T,
Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al: Coordinated
silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic
target of histone modification in aggressive B-Cell lymphomas.
Cancer Cell. 22:506–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mitxelena J, Apraiz A, Vallejo-Rodríguez
J, Malumbres M and Zubiaga AM: E2F7 regulates transcription and
maturation of multiple microRNAs to restrain cell proliferation.
Nucleic Acids Res. 44:5557–5570. 2016. View Article : Google Scholar :
|
